Conversion of locally advanced to resectable pancreatic body cancer aided by phosphoi us-32 brachytherapy (OncoSil)

Discussion Despite improvements in treatment, pancreatic cancer has the lowest survival rate of all major cancers (8.2% 5-year survival).3 Most patients are not candidates for curative-intent surgery due to locally advanced features (vascular invasion) or distant metastases. Resection of LAPC after chemoradiotherapy has been described, although R0 rates vary widely4 Brachytherapy is a form of radiation therapy where a radiation source is implanted next to the area requiring treatment. Bhutani MS, Kalpman JB, Tuli R, et a I. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advance pancreatic cancer (OncoPaC-1) Technical details and study protocol.